Krystal Biotech Profit Margin

The latest profit margin for KRYS is 54.82% as of June 2026. That compares with 40.85% in the prior-year period — up 34.2% year over year. That is above the Healthcare sector average of 21.34%. Investors often review this figure alongside Krystal Biotech's historical trend and sector peers before judging valuation or financial health.

Over the past year, KRYS's profit margin moved from 40.85% to 54.82% — a 34.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Krystal Biotech's valuation or profitability profile.

Against Healthcare companies, KRYS currently prints 54.82% for profit margin, while the sector average sits near 21.34%. That is roughly 156.9% above the sector mean. Large gaps often invite a closer look at Krystal Biotech's growth, margins, and balance sheet.

Profit Margin shows how effectively Krystal Biotech converts resources into returns. At 54.82%, KRYS may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 40.85% in the prior-year period — up 34.2% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting KRYS's profit margin (54.82%), review year-over-year change from 40.85%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.